Prevention Drugs and Wearables
Gio@gio
The idea
I believe healthcare is shifting from treating sickness to preventing it, led by weight-loss and metabolic drugs people take for years plus wearable sensors that let healthy people track their own health. I own the two drug leaders alongside a smaller group of challengers, the suppliers who make the vials and parts these drugs need regardless of which brand wins, and the companies behind the sensors people wear. I keep the basket broad rather than betting on any single name, hold a cash cushion, and plan to hold for years since this is a slow structural shift, not a quick trade.
What will be bought
- Wearable glucose sensors and health trackers let people monitor their own health daily without visiting a doctor, enabling the prevention habits this take is built on. · DexCom, Inc.It makes glucose sensors and sells Stelo directly to people without insulin, while recent research backing sensor use in type-two diabetics supports wider adoption beyond traditional diabetes treatment., Abbott LaboratoriesIt makes Libre sensors and sells Lingo to healthy people tracking their own glucose, representing the wearables side of preventive health monitoring outside the traditional diabetes market., Garmin Ltd.Its watches track heart rate, sleep and fitness data, letting people monitor their daily health as part of the broader prevention and wellness trend., iRhythm Technologies, Inc.It makes Zio, a wearable patch that detects heart rhythm problems early before they progress to stroke or emergency events, catching health issues through preventive monitoring.30%
- Injection pens and vials require specialized parts, equipment and manufacturing services, so these suppliers benefit regardless of which weight-loss drug brand leads the market. · West Pharmaceutical Services, Inc.It makes the stoppers, seals and pen components that go into injectable drugs, so it earns revenue whichever weight-loss shot becomes the market standard., Thermo Fisher Scientific Inc.It manufactures drugs under contract and supplies laboratories and production tools to drugmakers, so growing demand for weight-loss drugs increases work for its manufacturing business., Danaher CorporationIt supplies the equipment and consumables used to manufacture biologic drugs, so high-volume production of prevention therapies drives demand for its products., Stevanato Group S.p.A.It makes glass vials, syringes and pen cartridges that every injectable weight-loss drug requires, earning revenue as shot volumes grow across the industry., Medpace Holdings, Inc.It runs clinical trials for smaller drug companies developing new obesity treatments, so a competitive race for next-generation drugs generates more trial work.27%
- These companies sell the most weight-loss drugs today, so they capture the initial growth as more people take them for long-term health management. · Eli Lilly and CompanyIt sells Zepbound and the Foundayo pill, which recently won European regulatory approval, making it the largest way to own the shift toward weight-loss drugs as a long-term health tool for healthy people., Novo Nordisk A/SIt makes Wegovy and its pill version, holding the position of second-largest leader in long-term weight-loss drugs even as competitors gain market share.19%
- Newer drugs and alternative delivery methods could capture share from today's leaders, providing upside if the prevention market expands beyond the current options. · Amgen Inc.It is developing a weight-loss shot taken once a month, which could make long-term adherence easier and provide an alternative to weekly injections., Hims & Hers Health, Inc.It sells weight-loss treatments directly to consumers online and is expanding internationally, providing an alternative channel for prevention drugs to reach healthy people outside traditional healthcare., Viking Therapeutics, Inc.It is a smaller drug company developing its own obesity shot and a pill entering late-stage trials, offering potential alternatives if the clinical results prove competitive with established leaders., Structure Therapeutics Inc.It is developing a lower-cost GLP-1 pill that could make prevention drugs accessible to far more healthy people, representing a higher-risk bet on a differentiated manufacturing approach.14%
- Cash10%